AB0916 ASSESSMENT OF PSORIATIC ARTHRITIS IMPACT OF DISEASE (PSAID-12) QUESTIONNAIRE FOR EVALUATIONS OF 6-YEARS TREAT-TO-TARGET STRATEGY OUTCOMES

Abstract

BackgroundThe 12-item psoriatic arthritis impact of disease questionnaire (PSAID-12) have been found to be a reliable instrument to specifically assess the impact of psoriatic arthritis (PsA) for the patients (pts) as well as predictive of long-term outcomes [1]. There are no data about use of the PsAID-12 for evaluation of long-term outcomes of treat to target (T2T) strategy in PsA pts.Objectivesto assess the PSAID-12 for evaluations of 6-years outcomes of T2T strategy in PsA.Methods50 (M/F–24/26) PsA pts fulfilling CASPAR criteria were included. Mean age 45±12.1 yrs, median (Me) PsA duration 82 [66;97] month (mos), Me follow-up 72 [58;89] mos. At the early stage (PsA duration≤2 yrs) all pts were treated according to T2T study within 24 mos. At 6 years follow-up all pts underwent standard clinical examination (tender joint count (TJS), swollen joint count (SJC), patient global assessment disease activity (PtGA), CRP (mg/l), skin psoriasis (PsO) by BSA (%), presence of nail PsO, enthesitis dactylitis, DAPSA and completed PsAID-12. PsAID-12 score≤ 4 is considered as a “patient-acceptable status symptoms” (PASS). PsAID-12 > 4 is considered as worse quality of life. DAPSA remission (REM-DAPSA) ≤4 and low disease activity (LDA) ≤14, moderate activity (Mo)≤28, high activity >28 were calculated. Me [Q25-Q75], M±SD, Spearman’s correlation, Mann-Whitney test were performed. All p<0.05 were considered to indicate statistical significance.ResultsAt 6 yrs follow-up REM-DAPSA were seen in 17 out of 50 pts (34%), LDA in 15 out of 50 (30%) pts. Mean total PsAID-12 score was 2.62±2.1. PASS was seen in 38 out of 50 pts (76%). PsAID-12 significantly associated with the PsA activity parameters: TJC (r=0.73, p<0.05), SJC (r=0.55, p<0.05), PtGA (r=0.77, p<0.05), CRP (r=0.55, p<0.05) and DAPSA (r=0.75, p<0.05). PsAID>4 significantly correlated with presence of dactylitis (r=0.33, p<0.05), skin severity (BSA>3) and presence nails PsO (r=0.41/r=0.38) accordingly. In pts with REM/LDA by DAPSA total PsAID score was significantly lower compare to pts with Mo/High activity - 1.34±0.99 and 4.89±1.84, accordingly (p<0.0001). All pts with REM/LDA status is achieved PASS by PsAID.ConclusionIn our clinical practice PsAID-12 associated with joint and skin severity in PsA pts. PsAID-12 is useful instrument for evaluating of the long-term T2T outcomes, including REM/LDA by DAPSA.